Apply to trial NCT06617481

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 2Drug trial

PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence

Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer. The research is being done to study the capability of 18F-rhPSMA-7.3 (flotufolastat F-18) PET scan to detect prostate cancer when there are very low levels of Prostate-Specific Antigen (PSA) following previous radical prostatectomy surgery.

How this works

  1. Answer a few questions

    About 5 to 10 minutes. Skip-friendly where possible.

  2. We forward your profile to the study team

    We send your contact details and a short fit summary to the official trial contacts, with you copied.

  3. The team reaches out to schedule screening

    Usually within a few business days, via the contact you give.

We save your progress under this email and copy you when we send your application to the study team.

By clicking Start, you agree to our terms of service, including sharing your contact details and fit summary with official trial contacts if you submit.